Aeon Biopharma Stock Performance
| AEON Stock | 1.16 0.05 4.50% |
On a scale of 0 to 100, AEON Biopharma holds a performance score of 6. The firm shows a Beta (market volatility) of -1.51, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning AEON Biopharma are expected to decrease by larger amounts. On the other hand, during market turmoil, AEON Biopharma is expected to outperform it. Please check AEON Biopharma's daily balance of power, price action indicator, as well as the relationship between the semi variance and treynor ratio , to make a quick decision on whether AEON Biopharma's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AEON Biopharma are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, AEON Biopharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:72 | Last Split Date 2025-02-26 |
1 | Will AEON Biopharma Inc. outperform the market - Weekly Stock Recap Low Risk Entry Point Guides - newser.com | 10/23/2025 |
2 | Acquisition by Carter Eric G of 16260 shares of AEON Biopharma, at 14.4 subject to Rule 16b-3 | 11/05/2025 |
3 | AEON Biopharma Reports Positive and Robust Biosimilarity Results Identical Amino Acid Sequence and Highly Similar Functional Analysis Data | 11/13/2025 |
4 | AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth | 11/14/2025 |
5 | Will AEON Biopharma Inc. Class stock beat international competition - Earnings Trend Report Precise Trade Entry Recommendations - newser.com | 11/17/2025 |
6 | AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling | 11/20/2025 |
7 | Can AEON Biopharma Inc. Class stock retain market dominance - July 2025 Fed Impact Growth Focused Entry Point Reports - Newser | 12/02/2025 |
8 | How AEON Biopharma Inc. Class stock performs in volatility spikes - Quarterly Market Review Fast Gain Stock Trading Tips - Newser | 12/04/2025 |
9 | AEON Biopharma Announces Execution of Exchange Agreement with Daewoong | 12/15/2025 |
10 | What insider trading reveals about AEON Biopharma Inc. stock - 2025 Technical Patterns Growth Focused Entry Reports - | 12/18/2025 |
11 | Aug EndMonth How AEON Biopharma Inc stock benefits from global expansion - Weekly Profit Recap Risk Managed Investment Strategies - moha.gov.vn | 12/24/2025 |
12 | AEON integrates scan-to-pay technology with OKXs X Layer network | 12/31/2025 |
AEON Biopharma Relative Risk vs. Return Landscape
If you would invest 94.00 in AEON Biopharma on October 7, 2025 and sell it today you would earn a total of 22.00 from holding AEON Biopharma or generate 23.4% return on investment over 90 days. AEON Biopharma is currently generating 0.6122% in daily expected returns and assumes 7.5839% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than AEON, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AEON Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AEON Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AEON Biopharma, and traders can use it to determine the average amount a AEON Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0807
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AEON | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average AEON Biopharma is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AEON Biopharma by adding it to a well-diversified portfolio.
AEON Biopharma Fundamentals Growth
AEON Stock prices reflect investors' perceptions of the future prospects and financial health of AEON Biopharma, and AEON Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AEON Stock performance.
| Return On Asset | -1.29 | ||||
| Current Valuation | 27.65 M | ||||
| Shares Outstanding | 11.64 M | ||||
| Price To Sales | 97.16 X | ||||
| EBITDA | (27.73 M) | ||||
| Net Income | 42.01 M | ||||
| Total Debt | 12.96 M | ||||
| Book Value Per Share | (1.37) X | ||||
| Cash Flow From Operations | (20.29 M) | ||||
| Earnings Per Share | (13.91) X | ||||
| Market Capitalization | 10.95 M | ||||
| Total Asset | 3.14 M | ||||
| Retained Earnings | (431.6 M) | ||||
| Working Capital | (12.56 M) | ||||
About AEON Biopharma Performance
By examining AEON Biopharma's fundamental ratios, stakeholders can obtain critical insights into AEON Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AEON Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 15.37 | 16.14 | |
| Return On Capital Employed | (5.97) | (5.67) | |
| Return On Assets | 15.37 | 16.14 | |
| Return On Equity | (1.32) | (1.26) |
Things to note about AEON Biopharma performance evaluation
Checking the ongoing alerts about AEON Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AEON Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AEON Biopharma is way too risky over 90 days horizon | |
| AEON Biopharma may become a speculative penny stock | |
| AEON Biopharma appears to be risky and price may revert if volatility continues | |
| AEON Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| AEON Biopharma generates negative cash flow from operations | |
| AEON Biopharma has a poor financial position based on the latest SEC disclosures | |
| About 19.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: AEON integrates scan-to-pay technology with OKXs X Layer network |
- Analyzing AEON Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AEON Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining AEON Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AEON Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AEON Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AEON Biopharma's stock. These opinions can provide insight into AEON Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AEON Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in AEON Stock, please use our How to Invest in AEON Biopharma guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AEON Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of AEON Biopharma is measured differently than its book value, which is the value of AEON that is recorded on the company's balance sheet. Investors also form their own opinion of AEON Biopharma's value that differs from its market value or its book value, called intrinsic value, which is AEON Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AEON Biopharma's market value can be influenced by many factors that don't directly affect AEON Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AEON Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if AEON Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AEON Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.